The QALY is a measure for the number of years someone still may expect, corrected for their quality.
To investigate the quality of the genetic test, the CCS diagnostic rate, sample-specific concurrence and cellularity of the TE biopsy were evaluated for each biopsy practitioner and corrected for embryo quality and batches of reagents used for the qPCR-based aneuploidy screening over the study period.
Costs are expressed in monetary terms while health gains are generally expressed in terms of quality-adjusted life years (QALYs), i.e. the amount of life time gained by the intervention corrected for the quality of life (QoL) during that time, with a QoL score of 1 representing perfect health and a QoL score of 0 representing the state of being dead [ 2].
The QALY loss for fatal cases was estimated as the average life-expectancy corrected for the expected quality of life in those years [9].
When the utilities were corrected for decrease in quality of life, the QALY gain was higher for the bazedoxifene cohort, leading to better cost-effectiveness.
To correct for technical quality between the different samples, each amplicon signal was normalized to an internal positive control which carries the corresponding mark and is not affected by the reprogramming (satellite alpha or gene desert-12 amplicons in the case of H3K9me2/3 or PABPC1 amplicon in the case of pan-H4ac).
Known jumps were corrected for and some poor quality data were eliminated manually.
These counts were corrected for polymorphisms in a quality score-specific manner, as above, but using CDS-specific estimates of polymorphism rates.
Based on the incidence rates of adverse events for both treatments, utilities were corrected for the decrease in quality of life associated with adverse events (Table 2).
We used a weighted regression model to assess the association between early migration and late aseptic revision corrected for match score, RSA study quality, survival study quality, number of TKP in the RSA studies, and number of TKP in the survival studies.
